Search - tctmd.com

Displaying 561 - 580 of 740

Sort: Relevancy | Date

Presentation

Case Presentation: 62 yo Woman With Severe AS and MS, NYHA class IV

Presenter: Mike Dyal

October 30, 2015

News Daily News

年轻女性 STEMI 患者在院内死亡的可能性高于男性

L.A. McKeown

October 28, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

Presentation

Temporal Trends and Sex Differences in Revascularization and Outcomes of STEMI in Younger Adults in the United States

Presenter: S. Khera

October 27, 2015

News Daily News

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

Todd Neale

October 26, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

与预期相反，研究发现冠状动脉微血管功能障碍无性别差异

Yael L. Maxwell

September 23, 2015

News Daily News

En Contra de lo que cabría Esperar, el Estudio No halla Diferencia de Género en la Disfunción Microvascular Coronaria

Yael L. Maxwell

September 23, 2015

News Daily News

Contrary to Expectations, Study Finds No Sex Difference in Coronary Microvascular Dysfunction

Yael L. Maxwell

September 23, 2015

Presentation

Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Pts With Angina in the Absence of Obstructive CAD

Presenter: Y. Kobayashi

September 22, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Registry Charts Trends in Mechanical Circulatory Support During PCI

L.A. McKeown

September 14, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

August 26, 2015

News Industry News

TriVascular Technologies raises $10m, launches study of EVAR in women

August 24, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

Advertisement

Case Presentation: 62 yo Woman With Severe AS and MS, NYHA class IV

年轻女性 STEMI 患者在院内死亡的可能性高于男性

Younger Women With STEMI More Likely Than Men to Die In-Hospital

Younger Women With STEMI More Likely Than Men to Die In-Hospital

Temporal Trends and Sex Differences in Revascularization and Outcomes of STEMI in Younger Adults in the United States

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

与预期相反，研究发现冠状动脉微血管功能障碍无性别差异

En Contra de lo que cabría Esperar, el Estudio No halla Diferencia de Género en la Disfunción Microvascular Coronaria

Contrary to Expectations, Study Finds No Sex Difference in Coronary Microvascular Dysfunction

Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Pts With Angina in the Absence of Obstructive CAD

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Registry Charts Trends in Mechanical Circulatory Support During PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

TriVascular Technologies raises $10m, launches study of EVAR in women

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content